Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.17
+0.05000.62%
Post-market: 8.170.00000.00%17:49 EDT
Volume:6.15M
Turnover:49.61M
Market Cap:2.09B
PE:-5.43
High:8.20
Open:8.12
Low:7.92
Close:8.12
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.93
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.60
PE(LYR):6.75

Loading ...

US Research Roundup-Alnylam Pharmaceuticals, Carvana, MongoDB

Reuters
·
Sep 30

BioCryst Pharmaceuticals, Inc. : JP Morgan Raises Target Price to $13 from $12

THOMSON REUTERS
·
Sep 30

Will Japan Pediatric Approval Change BioCryst Pharmaceuticals (BCRX) Narrative

Simply Wall St.
·
Sep 24

GlycoEra Names Andrea Matthews Chief Business Officer

Reuters
·
Sep 23

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

MT Newswires Live
·
Sep 10

RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13

MT Newswires Live
·
Sep 10

BioCryst Pharmaceuticals, Inc. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $11 from $13

THOMSON REUTERS
·
Sep 10

U.S. Research Roundup-Caseys General Stores, Targa Resources, United Rentals

Reuters
·
Sep 10

BioCryst Pharmaceuticals Price Target Maintained with a $16.00/Share by Needham

Dow Jones
·
Sep 09

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

TIPRANKS
·
Sep 09

BioCryst announces Japan MHLW marketing approval for Orladeyo

TIPRANKS
·
Aug 25

BioCryst Says Japan Approves Orladeyo for Pediatric HAE Patients Aged 2-11

Reuters
·
Aug 25

BioCryst Announces Approval of Orladeyo® for Pediatric Hae Patients in Japan

THOMSON REUTERS
·
Aug 25

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

Simply Wall St.
·
Aug 15

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

Simply Wall St.
·
Aug 12

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush

Dow Jones
·
Aug 07

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06